To promote the work of its member centers, AACI publishes Commentary, an editorial series focusing on major issues of common interest to North American cancer centers.
Each AACI Commentary is written by a cancer center leader or subject matter expert and distributed by email to the more than 2,500 readers of the AACI Update newsletter.
The publication is designed to cover a specific topic in 750-1,000 words. Recommendations for topics and authors are encouraged.
As AACI continues to closely monitor the coronavirus pandemic, we are pleased to share this overview of ways that our Corporate Roundtable members are directly supporting cancer centers and their patients during these unprecedented and challenging times.
The AACI Corporate Roundtable provides a forum for AACI cancer centers to address topics of mutual interest with their pharmaceutical industry colleagues. This interaction has the potential to advance the progress of research and ultimately benefit patients with cancer and their families.
COVID-19 assistance from our corporate partners covers a wide range of activities, from maintaining the integrity of clinical trials and ensuring the flow of protective equipment and other supplies to cancer centers, to accelerating vaccine development and providing medicine to patients facing financial hardship.
AACI thanks its Corporate Roundtable members for sharing information about their cancer-related COVID-19 work and for their ongoing support and commitment: AbbVie, Amgen, Astellas, Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Kite, Lilly, Merck, Pfizer, and Takeda Oncology.
Read the May 2020 Commentary.
COVID-19: How AACI’s Corporate Partners Are Helping Cancer Centers and Their Patients Weather the Pandemic
COVID-19: What AACI Cancer Centers Are Doing to Mitigate Risks
By AACI Staff
Perspectives From the NCI Director: Homecoming and the NCI FY 2020 Budget
By Norman E. Sharpless, MD
Looking Ahead: Forging a Path for 2020 and Beyond
By Jennifer W. Pegher, MA
Bridging the Cost Chasm: Empowering Clinical Trials Offices to Negotiate With Industry Partners
By Aleksandar Zafirovski, MBA
Artificial Intelligence, Workforce Training, Patient Advocacy & More: Reflections on the 2019 AACI/CCAF Annual Meeting
By Michael B. Kastan, MD, PhD
Less Paper, Better Trials: Recommendations for Implementing an Electronic Regulatory Document Management System
By the AACI Regulatory File Management Working Group
A Future Without HPV-Related Cancers is Within Reach: Eliminating Cervical Cancer is the First Step
By Anna R. Giuliano, PhD
Simplifying Clinical Trials: Using Technology to Improve Operations
By the AACI Shared Investigator Platform (SIP) Task Force
Disclose and Manage: Recommendations From the AACI Conflict of Interest Task Force
By Karen E. Knudsen, MBA, PhD, and Leonidas C. Platanias, MD, PhD
Inventing the Future of Oncology Nursing
By Laura Fennimore, DNP, RN, NEA-BC
Ensuring Patient Access to CAR T Therapy: AACI Responds to CMS Medicare Coverage Proposal
By Richard Bondi and Clint Divine
A Revolution in Cancer Care: AACI's New Initiative Will Establish Best Practices in CAR T Therapy
By Joseph McGuirk, DO
A Legislation Library to Benefit AACI Cancer Centers
By Roy A. Jensen, MD
Zip Code vs. Genetic Code: Breaking Down Cancer Disparities in Philadelphia
By Karen E. Knudsen, PhD
Satisfaction with Oncology Quality and Clinical Operations: A survey from the AACI Physician Clinical Leadership Initiative (PCLI)
By Morgan Dodson, Michael Neuss, Laura Hutchins, Richard Lauer, John Sweetenham, Nathan Levitan, Martha Mims, Mohammed Milhem, Craig Bunnell, Dan Mulkerin, Randall F. Holcombe
SF CAN: A City Working Together to Fight Cancer
By Alan Ashworth, PhD, FRS
Integrating Clinical Research into Clinical Care
By Martha Mims, MD, PHD & Sarah McNees, PHD